RTP Mobile Logo
Select Publications

Berdeja JG et al. Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. ASCO 2020;Abstract 8505.

Cho S-F et al. Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy. Front Immunol 2018;9:1821. Abstract

Costa LJ et al. Interim results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) 2 + 1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM). EHA 2020;Abstract S205.

Facon T et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380(22):2104-15. Abstract

Giri S et al. Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials. ASCO 2020;Abstract 8540.

Hansen JD et al. Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma. J Med Chem 2020;63(13):6648-76. Abstract

Kumar S et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21(10)1317-30. Abstract

Lonial S et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21(2):207-21. Abstract

Mailankody S et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Update of the phase 1/2 EVOLVE study (NCT03430011). ASCO 2020;Abstract 8504.

Mateos MV et al. A phase 1 study of teclistamab, a humanized B-cell maturation antigen (BCMA) X CD3 bispecific antibody, for the treatment of relapsed and/or refractory multiple myeloma (RRMM). EHA 2020;Abstract S206.

Moreau P et al. Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): Interim analysis of a phase 3, randomized, open-label study. EHA 2020;Abstract LB2603.

Munshi NC et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. ASCO 2020;Abstract 8503.

Neelapu SS et al. Chimeric antigen receptor T-cell therapy — Assessment and management of toxicities. Nat Rev Clin Oncol 2018;15(1):47-62. Abstract

Nooka AK et al. Treatment options for relapsed and refractory multiple myeloma. Blood 2015;125(20):3085-99. Abstract

Orlowski RZ, Lonial S. Integration of novel agents into the care of patients with multiple myeloma. Clin Cancer Res 2016;22(22):5443-52. Abstract

Perrot A et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 2018;132(23):2456-64. Abstract

Rajkumar SV et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117(18):4691-5. Abstract

Richardson PG et al. First-in-human phase 1 study of the novel CELMOD agent CC-92480 combined with dexamethasone in patients with relapsed/refractory multiple myeloma. EHA 2020;Abstract S208.

Schjesvold F et al. OCEAN: A randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. Future Oncol 2020;16(11):631-41. Abstract

Schmidt J et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 2013;27(12):2357-65. Abstract

Stadtmauer EA et al. CRISPR-engineered T cells in patients with refractory cancer. Science 2020;367(6481):eaba7365. Abstract

Voorhees PM et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial. Blood 2020;136(8):936-45. Abstract

Yong K et al. Multiple myeloma: Patient outcomes in real-world practice. Br J Haematol 2016;175(2):252-64. Abstract